Breakout Setups
BBIO appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
BRIDGEBIO PHARMA INC (BBIO) Stock Price & Overview
NASDAQ:BBIO • US10806X1028
Current stock price
74.44 USD
-1.74 (-2.28%)
At close:
74.44 USD
0 (0%)
After Hours:
The current stock price of BBIO is 74.44 USD. Today BBIO is down by -2.28%. In the past month the price increased by 8.62%. In the past year, price increased by 105.04%.
BBIO Key Statistics
52-Week Range31.77 - 84.94
Current BBIO stock price positioned within its 52-week range.
1-Month Range68.83 - 79.62
Current BBIO stock price positioned within its 1-month range.
- Market Cap
- 14.431B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.78
- Dividend Yield
- N/A
BBIO Stock Performance
Today
-2.28%
1 Week
-4.20%
1 Month
+8.62%
3 Months
-4.40%
Longer-term
6 Months +37.19%
1 Year +105.04%
2 Years +190.55%
3 Years +412.67%
5 Years +33.12%
10 Years N/A
BBIO Stock Chart
BBIO Stock Screens
BBIO currently appears in the following ChartMill screener lists.
BBIO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BBIO. When comparing the yearly performance of all stocks, BBIO is one of the better performing stocks in the market, outperforming 89.77% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBIO. BBIO may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BBIO Earnings
On February 24, 2026 BBIO reported an EPS of -1 and a revenue of 154.18M. The company missed EPS expectations (-32.11% surprise) and beat revenue expectations (2.94% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$1.00
Revenue Reported154.178M
EPS Surprise -32.11%
Revenue Surprise 2.94%
BBIO Forecast & Estimates
29 analysts have analysed BBIO and the average price target is 102.45 USD. This implies a price increase of 37.62% is expected in the next year compared to the current price of 74.44.
For the next year, analysts expect an EPS growth of 46.69% and a revenue growth 87.45% for BBIO
Analysts
Analysts85.52
Price Target102.45 (37.63%)
EPS Next Y46.69%
Revenue Next Year87.45%
BBIO Groups
Sector & Classification
BBIO Financial Highlights
Over the last trailing twelve months BBIO reported a non-GAAP Earnings per Share(EPS) of -3.78. The EPS decreased by -22.33% compared to the year before.
Income Statements
Revenue(TTM)502.08M
Net Income(TTM)-724.93M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%28.57%
Sales Q2Q%2521.18%
EPS 1Y (TTM)-22.33%
Revenue 1Y (TTM)126.26%
BBIO Ownership
Ownership
Inst Owners93.02%
Shares193.86M
Float167.90M
Ins Owners4.08%
Short Float %13.92%
Short Ratio8.96
BBIO Latest News, Press Relases and Analysis
12 days ago - By: Chartmill
BBIO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBIO
Company Profile
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Company Info
IPO: 2019-06-27
BRIDGEBIO PHARMA INC
3160 Porter Dr., Suite 250
Palo Alto CALIFORNIA 94301 US
CEO: Neil Kumar
Employees: 837
Phone: 13026587581
BRIDGEBIO PHARMA INC / BBIO FAQ
What does BBIO do?
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. The company is headquartered in Palo Alto, California and currently employs 834 full-time employees. The company went IPO on 2019-06-27. The company discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. The company also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
What is the current price of BBIO stock?
The current stock price of BBIO is 74.44 USD. The price decreased by -2.28% in the last trading session.
Does BBIO stock pay dividends?
BBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of BBIO stock?
BBIO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists BBIO stock?
BBIO stock is listed on the Nasdaq exchange.
What sector and industry does BRIDGEBIO PHARMA INC belong to?
BRIDGEBIO PHARMA INC (BBIO) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for BBIO stock?
BRIDGEBIO PHARMA INC (BBIO) currently has 837 employees.